Effect of pylorus-preserving pancreaticoduodenectomy on serum levels of 5-fluorouracil during S-1 treatment for pancreaticobiliary malignancy

Japanese Journal of Cancer and Chemotherapy

Volumn 37, Issue 8, 2010, Pages 1503-1506

  Muneoka, Katsuki ^a   Shirai, Yoshio ^b   Sasaki, Masataka ^a   Wakai, Toshifumi ^b   Sakata, Jun ^b   Kanda, Junkichi ^c   Wakabayashi, Hiroyuki ^c   Hatakeyama, Katsuyoshi ^b  

^a Niitsu Medical Center Hospital   (Japan)

^b NIIGATA UNIVERSITY GRADUATE SCHOOL OF MEDICAL AND DENTAL SCIENCES   (Japan)

^c NIIGATA UNIVERSITY OF PHARMACY AND APPLIED LIFE SCIENCES   (Japan)

Author keywords

5 Fluorouracil; Antineoplastic chemotherapy; Biliary neoplasms; Pharmacokinetic monitoring

Indexed keywords

FLUOROURACIL; GIMERACIL PLUS OTERACIL POTASSIUM PLUS TEGAFUR;

ARTICLE; BILE DUCT CANCER; BILE DUCT RESECTION; BILIOENTERIC ANASTOMOSIS; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL ARTICLE; COMPARATIVE STUDY; DRUG BLOOD LEVEL; EPIPHORA; GALLBLADDER CANCER; HEPATIC DUCT; HUMAN; LAPAROTOMY; LIVER RESECTION; MULTIPLE CYCLE TREATMENT; PANCREAS CANCER; PANCREATICOBILIARY MALIGNANCY; PANCREATICODUODENECTOMY; PYLORUS PRESERVING PANCREATICODUODENECTOMY; TREATMENT RESPONSE; VATER PAPILLA CARCINOMA;

EID: 79961109951     PISSN: 03850684     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (14)

1. Maehara Y: S-1 in gastric cancer a comprehensive review. Gastric Cancer 6(suppl 1): 2-8, 2003.
2. Hirata K, Horikoshi N, Aiba K, et al: Pharmacokinetic study of S-1, a novel oral fluorouracil antitumor drug. Clin Cancer Res 5(8): 2000-2005, 1999.
3. Kim WY, Nakata B, Hirakawa K, et al: Alternative pharmacokinetics of S-1 components. 5-fluorouracil, dihydrouracil and alpha-fluoro-beta-alanine after oral administration of S-1 following total gastrectomy. Cancer Sci 98(10): 1604-1608, 2007.
4. Ueno H, Okusaka T, Ikeda M, et al: A phase II study of S-1 in patients with advanced biliary tract cancer. Br J Cancer 91(10): 1769-1774, 2004. (Pubitemid 39664963)
5. JCOG and JSCO: Common terminology criteria for adverse events v3.0 (CTCAE). Int J Clin Oncol 9(suppl 3): 1-64, 2004.
6. Arai W, Hosoya Y, Hyodo M, et al: Alternate-day oral therapy with TS-1 for advanced gastric cancer. Int J Clin Oncol 9(3): 143-148, 2004. (Pubitemid 38899745)
7. Matsushima E, Yoshida K, Kitamura R, et al: Determination of S-1 and 5-fluorouracil in human plasma and urine using high-performance liquid chromatography and gas chromatography-negative ion chemical ionization mass spectrometry. J Chromatogr B Biomed Sci Appl 691 (1): 95-104, 1997. (Pubitemid 27168843)
8. Kruskal WH and Wallis WA: Use of ranks in one-criterion variance analysis. J Amer Stat Assn 47: 583-621, 1952.
9. Kochi M, Fujii M, Kanamori N, et al: Effect of gastrectomy on the pharmacokinetics of S-1, an oral fluoropyrimidine, in respectable gastric cancer patients. Cancer Chemother Pharmacol 60(5): 693-701, 2007. (Pubitemid 47247281)
10. Ueno H, Okusaka T, Ikeda M, et al: A phase I study of chemotherapy with gemcitabine and oral S-1 for advanced pancreatic cancer. Oncology 69(5): 421-427, 2005. (Pubitemid 41797919)